Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
16.80
-0.49 (-2.83%)
Nov 17, 2026, 3:00 PM CST
Aurisco Pharmaceutical Revenue
Aurisco Pharmaceutical had revenue of 385.61M CNY in the quarter ending September 30, 2026, a decrease of -7.10%. This brings the company's total for the last twelve months to 1.67B, up 3.07% year-over-year. In the year 2025, Aurisco Pharmaceutical had annual revenue of 1.70B with 15.03% growth. That makes Aurisco Pharmaceutical the 15,843rd largest company in the world by revenue and 2,863rd in China.
Revenue (ttm)
1.67B
Revenue Growth
+3.07%
P/S Ratio
4.08
Revenue / Employee
826.46K
Employees
2,026
Market Cap
6.78B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Aurisco Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.70B | 221.74M | 15.03% |
| Dec 31, 2024 | 1.48B | 213.21M | 16.89% |
| Dec 31, 2023 | 1.26B | 254.45M | 25.24% |
| Dec 31, 2022 | 1.01B | 204.71M | 25.48% |
| Dec 31, 2021 | 803.36M | 81.92M | 11.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.13B |
| Novogene | 2.30B |
| Jiangxi Fushine Pharmaceutical | 1.97B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.43B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Chengdu Easton Biopharmaceuticals | 1.30B |
| Bio-Thera Solutions | 1.05B |
| Daan Gene | 776.43M |